Stock Price Quote

MANKIND PHARMA LTD.

NSE : MANKINDBSE : 543904ISIN CODE : INE634S01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE1750.3010.5 (+0.6 %)
PREV CLOSE ( ) 1739.80
OPEN PRICE ( ) 1786.30
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3862
TODAY'S LOW / HIGH ( )1746.80 1786.30
52 WK LOW / HIGH ( )1240.75 1950
NSE1750.708.15 (+0.47 %)
PREV CLOSE( ) 1742.55
OPEN PRICE ( ) 1776.10
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 1750.70 (108)
VOLUME 84803
TODAY'S LOW / HIGH( ) 1747.05 1776.55
52 WK LOW / HIGH ( )1242 1949
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 03-07 1991
Management Info
Ramesh Juneja - Chairman Rajeev Juneja - Managing Director
Registered Office

Address 208,Okhla Industrial Estate,Phase - 111,
New Delhi,
Delhi-110020

Phone 011-46846700

Email investors@mankindpharma.com

Website www.mankindpharma.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

25Aug Tech Mahindra, Mankind Pharma and Gard
Tech Mahindra has partnered with IFS, the global cloud enterprise softwa..
24Aug Mankind Pharma gets nod to incorporate
Mankind Pharma has received approval for the incorporation of a wholly o..
02Aug Change in Directorate
Inter alia, approved:- Reappointment of Mr. Ramesh Juneja (DIN: 0028339..
02Aug Conversion of Stock Option
Inter alia, approved:- Reappointment of Mr. Ramesh Juneja (DIN: 0028339..
18Jul Mankind Pharma informs about board mee
Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosur..

Financials

in Millions
QTR Jun 23 ANNUAL 23
Net Profit4092.8312482.57
Gross Profit 5263.94 15628.36
Operating Profit 5969.0518601.64
Net Sales 23002.1181271.53

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Guj. Themis Biosyn (BSE)
peergroup  932.00 (5.36%)
M.Cap ( in Cr)1354.08
NGL Fine-Chem (BSE)
peergroup  2023.30 (1.54%)
M.Cap ( in Cr)1250.00
Dr. Reddy's Lab (BSE)
peergroup  5468.10 (0.53%)
M.Cap ( in Cr)91199.58
Pfizer (BSE)
peergroup  3863.15 (0.71%)
M.Cap ( in Cr)17673.04
Divi's Lab (BSE)
peergroup  3752.95 (0.61%)
M.Cap ( in Cr)99629.03

Shareholding Pattern

PROMOTERS 76.5%
MUTUAL FUNDS/UTI 3.92%
NON-INSTITUTION 14.68%
FI/BANKS/INSURANCE 0.55%
GOVERNMENT 0%
FII 0%

About Mankind Pharma Ltd.

Mankind Pharma Ltd. was incorporated in the year 1991. Its today's share price is 1750.3. Its current market capitalisation stands at Rs 70114.99 Cr. In the latest quarter, company has reported Gross Sales of Rs. 84716.97 Cr and Total Income of Rs.82899.36 Cr. The company's management includes Pradeep Chugh, Vivek Kalra, Bharat Anand, Vijaya Sampath, T P Ostwal, Surendra Lunia, Satish Kumar Sharma, Sheetal Arora, Rajeev Juneja, Ramesh Juneja.

It is listed on the BSE with a BSE Code of 543904 , NSE with an NSE Symbol of MANKIND and ISIN of INE634S01028. It's Registered office is at 208,Okhla Industrial Estate,Phase - 111New Delhi-110020, Delhi. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Bhagi Bhardwaj Gaur & Co, Deloitte Haskins & Sells LLP, Goel Gaurav & Co, SR Batliboi & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.